Lab research suggests more women could benefit from Herceptin
Herceptin may be effective against more types of breast cancer than previously thought, according to US research.
Herceptin, also known as trastuzumab, is often given to women with breast cancers that test positive for high levels of a protein known as HER2.
But HER2 could help fuel the growth of some breast cancers that are labelled HER2-negative, researchers at the University of Michigan Comprehensive Cancer Center discovered.
Read the whole article at Cancer Research UK
Reference
- Ithimakin, S., Day, K. C. et al. (2013). HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab Cancer Research DOI: 10.1158/0008-5472.CAN-12-3349
Keywords: Herceptin, trastuzumab, breast cancer, HER2-positive breast cancer, HER2-negative breast cancer, adjuvant therapy
26. 2. 2013 Cancer Research UK
